Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 19 Jan 2018 New trial record